Michael H Bloch1, Ahmad Qawasmi. 1. Yale Child Study Center, Yale University School of Medicine, New Haven, CT 06520, USA. michael.bloch@yale.edu
Abstract
OBJECTIVE: Several studies have demonstrated differences in omega-3 fatty acid composition in plasma and in erythrocyte membranes in patients with attention-deficit/hyperactivity disorder (ADHD) compared with unaffected controls. Omega-3 fatty acids have anti-inflammatory properties and can alter central nervous system cell membrane fluidity and phospholipid composition. Cell membrane fluidity can alter serotonin and dopamine neurotransmission. The goal of this meta-analysis was to examine the efficacy of omega-3 fatty acid supplementation in children with ADHD. METHOD: PubMed was searched for randomized placebo-controlled trials examining omega-3 fatty acid supplementation in children with ADHD symptomatology. The primary outcome measurement was standardized mean difference in rating scales of ADHD severity. Secondary analyses were conducted to determine the effects of dosing of different omega-3 fatty acids in supplements. RESULTS: Ten trials involving 699 children were included in this meta-analysis. Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms. Eicosapentaenoic acid dose within supplements was significantly correlated with supplement efficacy. No evidence of publication bias or heterogeneity between trials was found. CONCLUSION: Omega-3 fatty acid supplementation, particularly with higher doses of eicosapentaenoic acid, was modestly effective in the treatment of ADHD. The relative efficacy of omega-3 fatty acid supplementation was modest compared with currently available pharmacotherapies for ADHD such as psychostimulants, atomoxetine, or α(2) agonists. However, given its relatively benign side-effect profile and evidence of modest efficacy, it may be reasonable to use omega-3 fatty supplementation to augment traditional pharmacologic interventions or for families who decline other psychopharmacologic options.
OBJECTIVE: Several studies have demonstrated differences in omega-3 fatty acid composition in plasma and in erythrocyte membranes in patients with attention-deficit/hyperactivity disorder (ADHD) compared with unaffected controls. Omega-3 fatty acids have anti-inflammatory properties and can alter central nervous system cell membrane fluidity and phospholipid composition. Cell membrane fluidity can alter serotonin and dopamine neurotransmission. The goal of this meta-analysis was to examine the efficacy of omega-3 fatty acid supplementation in children with ADHD. METHOD: PubMed was searched for randomized placebo-controlled trials examining omega-3 fatty acid supplementation in children with ADHD symptomatology. The primary outcome measurement was standardized mean difference in rating scales of ADHD severity. Secondary analyses were conducted to determine the effects of dosing of different omega-3 fatty acids in supplements. RESULTS: Ten trials involving 699 children were included in this meta-analysis. Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms. Eicosapentaenoic acid dose within supplements was significantly correlated with supplement efficacy. No evidence of publication bias or heterogeneity between trials was found. CONCLUSION:Omega-3 fatty acid supplementation, particularly with higher doses of eicosapentaenoic acid, was modestly effective in the treatment of ADHD. The relative efficacy of omega-3 fatty acid supplementation was modest compared with currently available pharmacotherapies for ADHD such as psychostimulants, atomoxetine, or α(2) agonists. However, given its relatively benign side-effect profile and evidence of modest efficacy, it may be reasonable to use omega-3 fatty supplementation to augment traditional pharmacologic interventions or for families who decline other psychopharmacologic options.
Authors: Marlene P Freeman; Joseph R Hibbeln; Katherine L Wisner; John M Davis; David Mischoulon; Malcolm Peet; Paul E Keck; Lauren B Marangell; Alexandra J Richardson; James Lake; Andrew L Stoll Journal: J Clin Psychiatry Date: 2006-12 Impact factor: 4.384
Authors: Joshua D Brooks; Ginger L Milne; Huiyong Yin; Stephanie C Sanchez; Ned A Porter; Jason D Morrow Journal: J Biol Chem Date: 2008-02-10 Impact factor: 5.157
Authors: Ana A Liso Navarro; Elif M Sikoglu; Cailin R Heinze; Ryan C Rogan; Vivienne A Russell; Jean A King; Constance M Moore Journal: Behav Brain Res Date: 2014-05-19 Impact factor: 3.332
Authors: L Eugene Arnold; Andrea S Young; Martha A Belury; Rachel M Cole; Barbara Gracious; Adina M Seidenfeld; Hannah Wolfson; Mary A Fristad Journal: J Child Adolesc Psychopharmacol Date: 2017-02-03 Impact factor: 2.576
Authors: Stephen Bent; Robert L Hendren; Tara Zandi; Kiely Law; Jae-Eun Choi; Felicia Widjaja; Luther Kalb; Jay Nestle; Paul Law Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-03-12 Impact factor: 8.829